Otsuka Pharmaceutical Co., Ltd: PharmaVitae Profile
Introduction
This analysis examines the historical and forecast performance for Otsuka in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Highlights
Strategic insight into the prospects for Otsuka over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
This analysis examines the historical and forecast performance for Otsuka in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Otsuka's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Otsuka over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Otsuka's performance against key rivals in the prescription pharmaceutical sector
- Review the key drivers to Otsuka's pharmaceutical business to understand its outlook following IPO in December 2010
- Assess the strategies used by Otsuka to overcome the pending loss of patent expiry for its largest product, Abilify
Contents
EXECUTIVE SUMMARYKey findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Otsuka: PharmaVitae forecasts at a glance
Strategic insight
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Key findings
Latest prescription pharma product news
Q4 2010
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Q3 2009
Latest corporate news
Q3 2009
Q2 2009
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Acquisition of Pharmavite LLC
Growth of US diagnostic business
Acquisition of Ito Life Sciences
Acquisition of Interpharma Praha stock
Acquisition of Nutrition & Santé holding company
Current corporate structure
Pharmaceuticals business unit structure
Medical division
Consumer health division
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
APPENDIX
References
Abbreviations
Exchange rates
Skip to top